» Articles » PMID: 37167549

A Large-Scale Exome-Wide Association Study Identifies Novel Germline Mutations in Lung Cancer

Overview
Specialty Critical Care
Date 2023 May 11
PMID 37167549
Authors
Affiliations
Soon will be listed here.
Abstract

Genome-wide association studies have identified common variants of lung cancer. However, the contribution of rare exome-wide variants, especially protein-coding variants, to cancers remains largely unexplored. To evaluate the role of human exomes in genetic predisposition to lung cancer. We performed exome-wide association studies to detect the association of exomes with lung cancer in 30,312 patients and 652,902 control subjects. A scalable and accurate implementation of a generalized mixed model was used to detect the association signals for loss-of-function, missense, and synonymous variants and gene-level sets. Furthermore, we performed association and Bayesian colocalization analyses to evaluate their relationships with intermediate exposures. We systematically analyzed 216,739 single-nucleotide variants in the human exome. The loss-of-function variants exhibited the most notable effects on lung cancer risk. We identified four novel variants, including two missense variants (rs202197044 [ ( values of meta-analysis) = 3.60 × 10] and rs202187871 [ = 2.21 × 10]) and two synonymous variants (rs7447927 [ = 1.32 × 10] and rs140624366 [ = 2.97 × 10]). rs202197044 was significantly associated with emphysema (odds ratio, 3.55;  = 0.015), whereas rs7447927 was strongly associated with telomere length (β = 1.08; (FDR corrected value) = 3.76 × 10). Functional evidence of expression of quantitative trait loci, splicing quantitative trait loci, and isoform expression was found for the four novel genes. Gene-level association tests identified several novel genes, including (protection of telomeres 1), , , and . Our findings provide insights into the genetic architecture of human exomes and their role in lung cancer predisposition.

Citing Articles

POT1 tumour predisposition: a broader spectrum of associated malignancies and proposal for additional screening program.

Baptista Freitas M, Desmyter L, Badoer C, Smits G, Vandernoot I, T Kint de Roodenbeke D Eur J Hum Genet. 2024; 32(8):980-986.

PMID: 38839987 PMC: 11291874. DOI: 10.1038/s41431-024-01611-0.


Proteome-wide Mendelian randomization identifies causal plasma proteins in lung cancer.

Li H, Du S, Dai J, Jiang Y, Li Z, Fan Q iScience. 2024; 27(2):108985.

PMID: 38333712 PMC: 10850776. DOI: 10.1016/j.isci.2024.108985.


Lung Cancer Risk and Delivering on the Promise of the Genomic Era.

Arenberg D Am J Respir Crit Care Med. 2023; 208(3):226-228.

PMID: 37343299 PMC: 10395716. DOI: 10.1164/rccm.202306-1000ED.

References
1.
Yue X, Samaniego-Castruita D, Gonzalez-Avalos E, Li X, Barwick B, Rao A . Whole-genome analysis of TET dioxygenase function in regulatory T cells. EMBO Rep. 2021; 22(8):e52716. PMC: 8339674. DOI: 10.15252/embr.202152716. View

2.
Sharp N . Mutations matter even if proteins stay the same. Nature. 2022; 606(7915):657-659. DOI: 10.1038/d41586-022-01091-6. View

3.
Wang Y, Luo J, Alu A, Han X, Wei Y, Wei X . cGAS-STING pathway in cancer biotherapy. Mol Cancer. 2020; 19(1):136. PMC: 7472700. DOI: 10.1186/s12943-020-01247-w. View

4.
Bulik-Sullivan B, Loh P, Finucane H, Ripke S, Yang J, Patterson N . LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015; 47(3):291-5. PMC: 4495769. DOI: 10.1038/ng.3211. View

5.
Shen X, Song S, Li C, Zhang J . Synonymous mutations in representative yeast genes are mostly strongly non-neutral. Nature. 2022; 606(7915):725-731. PMC: 9650438. DOI: 10.1038/s41586-022-04823-w. View